Inactive Instrument

PALA PHAR

Equities

PAL

AU0000049462

Palla Pharma Limited Reaffirms Earnings Guidance for the Second Half of Fiscal 2020 and Fiscal 2021-22

August 30, 2020 at 11:15 pm

Palla Pharma Limited reaffirmed earnings guidance for the second half of fiscal 2020 and fiscal 2021-22. As previously communicated, the company expects a significant revenue and earnings skew to the second half of second half of 2020 as first MA sales start in the fourth quarter of 2020. Fiscal 2020 revenue is expected to be modestly lower to flat year over year with a significant uplift expected in the fiscal 2021-22.

Latest news about PALA PHAR

Palla Pharma Limited Announces Resignation of Mark Licciardo as Company Secretary	21/06/22	CI
Palla Pharma Limited Announces Resignation of Simon Moore as Non-Executive Director and Chairman	23/05/22	CI
Palla Pharma Limited Announces Iain Ross's Resignation from the Board	25/04/22	CI
Palla Pharma Limited Announces Board Resignations	21/04/22	CI
An unknown buyer acquired Palla Pharma Norway As from Palla Pharma Limited.	28/03/22	CI
A consortium of local Norwegian buyers acquired Palla Pharma (UK) Limited from Palla Pharma Limited.	28/03/22	CI
Palla Pharma Enters Voluntary Administration	17/12/21	MT
Palla Pharma Enters Sale, Leaseback Deal for Coolaroo Manufacturing Site; Shares Up Nearly 3%	26/11/21	MT
Palla Pharma : Taps Clover Exec for CFO Role; Shares Slip 3%	06/10/21	MT
Palla Pharma Limited Announces Chief Financial Officer Changes	05/10/21	CI
Transcript : Palla Pharma Limited, H1 2021 Earnings Call, Sep 30, 2021	30/09/21
Palla Pharma Limited Provides Earnings Guidance for the Second Half of 2021	30/09/21	CI
Palla Pharma Limited Reports Earnings Results for the Half Year Ended June 30, 2021	31/08/21	CI
Palla Pharma : Completes Regulatory Submissions to Ireland, Germany for Painkiller Product	23/06/21	MT
Palla Pharma : Appoints Alloga for UK Distribution Network	21/06/21	MT
Palla Pharma Limited Appoints Alloga UK Limited Widening Uk Distribution Network	20/06/21	CI
Palla Pharma : Names New CEO; Shares Soar 18%	26/05/21	MT
Palla Pharma Limited Appoints Giles Moss as Chief Executive Officer, Effective from September 1, 2021	26/05/21	CI
Palla Pharma : Launches Pain Relief Drug in UK	04/05/21	MT
Palla Pharma Limited Announces Launch of Its Co-Codamol 30/500 Caplet in the UK Market	03/05/21	CI
Palla Pharma Limited provides Production Partnership Update with M&A Pharmachem	03/05/21	CI
Palla Pharma Limited Auditor Raises 'Going Concern' Doubt	18/03/21	CI
Transcript : Palla Pharma Limited, 2020 Earnings Call, Feb 26, 2021	25/02/21
Palla Pharma Limited Provides Revenue Guidance for the Second Half of 2021	25/02/21	CI
Palla Pharma : Secures UK Approval for Manufacturing Site Change of Co-Codamol Tablets	18/02/21	MT

Chart PALA PHAR

Duration

Period

More charts

Company Profile

Palla Pharma Limited is an Australia-based vertically integrated pharmaceutical company. The Company's primary activities include production and distribution of Narcotic Raw Material (NRM), Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF) for supply to international pharmaceutical markets, and the production and distribution of poppy seed for supply to international culinary markets. The Company operates through two segments: Australia and Norway. Australia segment activities include Narcotic Raw Material and Poppy Seed production and distribution. Norway segment activities include Active Pharmaceutical Ingredient and Finished Dosage production and distribution. The Company has developed a water-based extraction technology, which is used in NRM production. It operates in Victoria and Tasmania; and northern hemisphere operations based in Norway. It sources its raw materials from Australian poppy growers in Tasmania, New South Wales, and Victoria.

Sector

More about the company